Home Page

Lightlake invites individual and institutional investors to attend interactive real-time presentation on Lightlake's progress with its opioid overdose reversal treatment and achievements in other areas.

NEW YORK, Feb. 27, 2015 /PRNewswire/ -- Lightlake Therapeutics Inc. ("Lightlake") (OTCQB: LLTP), a biopharmaceutical company developing addiction treatments based on its expertise in opioid antagonists, announced today that its Chief Executive Officer, Dr. Roger Crystal, and Chief Financial Officer, Kevin Pollack, will present at VirtualInvestorConferences.com on March 5th.

DATE:  Thursday, March 5, 2015

TIME:   11:30 AM EST

LINK:   http://virtualinvestorconferences.com > red "register/ watch event now" button

This will be a live, interactive online event where investors are invited to ask the company questions in real-time – both in the presentation hall as well as the association's "virtual trade booth." If attendees are not able to join the event live on the day of the conference, an on-demand archive will be available for 90 days.

It is recommended that investors pre-register and run the online system check to save time and receive event updates.

Recent Lightlake Highlights:

• Entered licensing deal with Adapt Pharma Limited subsidiary with respect to opioid overdose reversal treatment that includes potential milestone payments of more than $55 million, plus up to double-digit royalties.
• Fast Track designation for opioid overdose reversal treatment received from the United States Food and Drug Administration.
• Commenced trial for opioid overdose reversal treatment with the U.S. National Institute on Drug Abuse, part of the National Institutes of Health

About Lightlake Therapeutics Inc.

Lightlake Therapeutics Inc., a biopharmaceutical company, is using its expertise in opioid antagonists to build a platform of innovative intranasal naloxone solutions to common addictions and related disorders. Lightlake is developing a treatment to reverse opioid overdoses, which have reached epidemic proportions in the United States. Lightlake has collaborated on clinical trials with the National Institute on Drug Abuse, part of the National Institutes of Health, and has entered into a licensing deal with a subsidiary of Adapt Pharma Limited. Lightlake also has completed a Phase II clinical trial to treat Binge Eating Disorder. For more information please visit: http://www.lightlaketherapeutics.com (http://www.lightlaketherapeutics.com/).

About VirtualInvestorConferences.com

Since 2010, VirtualInvestorConferences.com, created by BetterInvesting (NAIC) and PR Newswire has been the only monthly virtual investor conference series that provides an interactive forum for presenting companies to meet directly with investors using a graphically-enhanced online platform.

Designed to replicate the look and feel of location-based investor conferences, Virtual Investor Conferences unites PR Newswire's leading-edge online conferencing and investor communications capabilities with BetterInvesting's extensive retail investor audience network.

Forward-Looking Statements

This press release contains forward-looking statements. These statements relate to future events or our future financial performance and involve known and unknown risks, uncertainties and other factors that may cause our or our industry's actual results, levels of activity, performance or achievements to be materially different from any future results, levels of activity, performance or achievements expressed, implied or inferred by these forward-looking statements. In some cases, you can identify forward-looking statements by terminology such as "may," "will," "should," "could," "would," "expects," "plans," "intends," "anticipates," "believes," "estimates," "predicts," "projects," "potential," or "continue" or the negative of such terms and other comparable terminology. These statements are only predictions based on our current expectations and projections about future events. You should not place undue reliance on these statements. Actual events or results may differ materially. In evaluating these statements, you should specifically consider various factors. These and other factors may cause our actual results to differ materially from any forward-looking statement. We undertake no obligation to update any of the forward-looking statements after the date of this press release to conform those statements to reflect the occurrence of unanticipated events, except as required by applicable law.

SOURCE Lightlake Therapeutics Inc.